Edward Fang is a medical professional with a broad experience in the field. He earned his Bachelor of Arts in Biology from Stanford University and then completed his medical education with a Doctor of Medicine from the David Geffen School of Medicine at UCLA and the UCLA School of Medicine. Throughout his career, Fang has held numerous senior positions in the pharmaceutical and biotech industry and played a key role in the development of various clinical projects.

Fang currently holds the position of Chief Medical Officer at Adaptive Phage Therapeutics, a company aimed at advancing the use of bacteriophages as a therapeutic approach to combat antibiotic-resistant infections. Prior to that, he served as Chief Medical Officer and Senior Vice President of Clinical Development at Micurx Pharmaceuticals, Inc., as well as Chief Medical Officer at Adenium Biotech Aps.

Before he joined the pharmaceutical industry, Fang worked in academia and healthcare settings, including his residency at the UCLA Department of Medicine. He was also the Editor-in-Chief at Epocrates, Inc., a provider of clinical decision-making tools for healthcare professionals.

With his diverse background in medicine, clinical development, and pharmaceuticals, Fang has made significant contributions to the healthcare industry. His expertise in clinical trials, therapeutic approaches, and medical writing has helped advance new treatments, and his research has been published in a variety of peer-reviewed publications.